Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX), a biomarker detection company, has scheduled its first quarter 2025 financial results announcement for May 12, 2025. The company will release its Q1 2025 results after market close, followed by a conference call at 4:30 p.m. E.T.
Investors can participate in the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 7353673. A live webcast will be available on the News & Events page of Quanterix's website, with the replay accessible for one year.
Kent Lake, holding 7.7% of Quanterix shares, has strongly criticized the company's amended merger agreement with Akoya Biosciences. The key issue is Quanterix's decision to remove shareholders' voting rights on the merger, despite reports showing nearly 3-to-1 opposition to the deal.
The statement highlights concerning financial impacts, noting that Quanterix's stock price has fallen 48% and enterprise value has declined over 100% since the merger announcement. Kent Lake directly challenges CEO Masoud Toloue's claim about the merger's "strong strategic merits."
In response, Kent Lake will continue its push to elect three new board members at the upcoming Annual Meeting, arguing that the current board has proven unable to represent shareholder interests effectively. The investor views this boardroom change as increasingly urgent following what they describe as a "value-destructive transaction" and "shocking disenfranchisement" of shareholders.
Quanterix and Akoya Biosciences have announced amended merger terms, revising their previous agreement. Under the new terms, Quanterix will issue approximately 7.76 million shares and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 in cash and 0.1461 Quanterix shares.
The revised deal structure results in 9 million fewer shares being issued compared to the original terms. Post-merger ownership will be split with Quanterix shareholders holding approximately 84% and Akoya shareholders owning 16% of the combined company.
The amended agreement has received approval from both companies' boards, with over 50% of Akoya shareholders agreeing to vote in favor. The merger is expected to close in Q2 2025, subject to standard closing conditions. Goldman Sachs is advising Quanterix, while Perella Weinberg Partners is serving as Akoya's financial advisor.
Kent Lake, holding 7.7% of Quanterix (NASDAQ: QTRX) shares, has filed a definitive proxy statement opposing the proposed merger with Akoya Biosciences (NASDAQ: AKYA). The investment firm has issued a letter to shareholders urging them to vote AGAINST both merger-related proposals at the upcoming special meeting scheduled for May 13, 2025.
Kent Lake characterizes the merger as 'value-destructive' and 'deeply unfair,' describing it as effectively a bailout for Akoya at Quanterix shareholders' expense. The firm has raised concerns about the transaction process and potential conflicts of interest among Quanterix board members. Shareholders can access additional voting information and resources at www.SaveQTRX.com.
Tikvah Management , owning approximately 1.5% of Quanterix Corp. (QTRX), has expressed serious concerns regarding Quanterix's recent agreement to purchase up to $30 million in convertible notes from Akoya Biosciences (AKYA).
The investment firm highlighted three major concerns: 1) Akoya's need for bridge financing indicates potential financial distress, 2) the timing of the capital commitment before the shareholder vote on the proposed Quanterix-Akoya merger is questionable, and 3) the convertible notes' terms are considered unfavorable to Quanterix shareholders.
Tikvah has reaffirmed its intention to vote AGAINST the proposed merger between Quanterix and Akoya at the upcoming Special Meeting, while reserving the right to change its position based on new developments.